Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Artizan has also entered into an option and license agreement with Biohaven aimed at developing and commercializing Artizans novel treatments for IBD in the U.S.